Literature DB >> 26811150

Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study.

Christopher D Jensen, Douglas A Corley, Virginia P Quinn, Chyke A Doubeni, Ann G Zauber, Jeffrey K Lee, Wei K Zhao, Amy R Marks, Joanne E Schottinger, Nirupa R Ghai, Alexander T Lee, Richard Contreras, Carrie N Klabunde, Charles P Quesenberry, Theodore R Levin, Pauline A Mysliwiec.   

Abstract

BACKGROUND: The fecal immunochemical test (FIT) is a common method for colorectal cancer (CRC) screening, yet its acceptability and performance over several rounds of annual testing are largely unknown.
OBJECTIVE: To assess FIT performance characteristics over 4 rounds of annual screening.
DESIGN: Retrospective cohort study.
SETTING: Kaiser Permanente Northern and Southern California. PATIENTS: 323 349 health plan members aged 50 to 70 years on their FIT mailing date in 2007 or 2008 who completed the first round of FIT and were followed for up to 4 screening rounds. MEASUREMENTS: Screening participation, FIT positivity (≥20 µg of hemoglobin/g), positive predictive values for adenoma and CRC, and FIT sensitivity for detecting CRC obtained from Kaiser Permanente electronic databases and cancer registries.
RESULTS: Of the patients invited for screening, 48.2% participated in round 1. Of those who remained eligible, 75.3% to 86.1% participated in subsequent rounds. Median follow-up was 4.0 years, and 32% of round 1 participants crossed over to endoscopy over 4 screening rounds-7.0% due to a positive FIT result. The FIT positivity rate (5.0%) and positive predictive values (adenoma, 51.5%; CRC, 3.4%) were highest in round 1. Overall, programmatic FIT screening detected 80.4% of patients with CRC diagnosed within 1 year of testing, including 84.5% in round 1 and 73.4% to 78.0% in subsequent rounds. LIMITATION: Screening detection, rather than long-term cancer prevention, was evaluated.
CONCLUSION: Annual FIT screening was associated with high sensitivity for CRC, with high adherence to annual follow-up screening among initial participants. The findings indicate that annual programmatic FIT screening is feasible and effective for population-level CRC screening. PRIMARY FUNDING SOURCE: National Institutes of Health.

Entities:  

Mesh:

Year:  2016        PMID: 26811150      PMCID: PMC4973858          DOI: 10.7326/M15-0983

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  30 in total

1.  The effect of fecal occult-blood screening on the incidence of colorectal cancer.

Authors:  J S Mandel; T R Church; J H Bond; F Ederer; M S Geisser; S J Mongin; D C Snover; L M Schuman
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Quality indicators for colonoscopy.

Authors:  Douglas K Rex; John L Petrini; Todd H Baron; Amitabh Chak; Jonathan Cohen; Stephen E Deal; Brenda Hoffman; Brian C Jacobson; Klaus Mergener; Bret T Petersen; Michael A Safdi; Douglas O Faigel; Irving M Pike
Journal:  Am J Gastroenterol       Date:  2006-04       Impact factor: 10.864

Review 3.  Quality indicators for colonoscopy.

Authors:  Douglas K Rex; Philip S Schoenfeld; Jonathan Cohen; Irving M Pike; Douglas G Adler; M Brian Fennerty; John G Lieb; Walter G Park; Maged K Rizk; Mandeep S Sawhney; Nicholas J Shaheen; Sachin Wani; David S Weinberg
Journal:  Gastrointest Endosc       Date:  2014-12-02       Impact factor: 9.427

4.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

Authors:  J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

5.  Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening.

Authors:  Enrique Quintero; Antoni Castells; Luis Bujanda; Joaquín Cubiella; Dolores Salas; Ángel Lanas; Montserrat Andreu; Fernando Carballo; Juan Diego Morillas; Cristina Hernández; Rodrigo Jover; Isabel Montalvo; Juan Arenas; Eva Laredo; Vicent Hernández; Felipe Iglesias; Estela Cid; Raquel Zubizarreta; Teresa Sala; Marta Ponce; Mercedes Andrés; Gloria Teruel; Antonio Peris; María-Pilar Roncales; Mónica Polo-Tomás; Xavier Bessa; Olga Ferrer-Armengou; Jaume Grau; Anna Serradesanferm; Akiko Ono; José Cruzado; Francisco Pérez-Riquelme; Inmaculada Alonso-Abreu; Mariola de la Vega-Prieto; Juana Maria Reyes-Melian; Guillermo Cacho; José Díaz-Tasende; Alberto Herreros-de-Tejada; Carmen Poves; Cecilio Santander; Andrés González-Navarro
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

6.  Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.

Authors:  James E Allison; Lori C Sakoda; Theodore R Levin; Jo P Tucker; Irene S Tekawa; Thomas Cuff; Mary Pat Pauly; Lyle Shlager; Albert M Palitz; Wei K Zhao; J Sanford Schwartz; David F Ransohoff; Joseph V Selby
Journal:  J Natl Cancer Inst       Date:  2007-09-25       Impact factor: 13.506

7.  Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs.

Authors:  Douglas A Corley; Christopher D Jensen; Amy R Marks; Wei K Zhao; Jolanda de Boer; Theodore R Levin; Chyke Doubeni; Bruce H Fireman; Charles P Quesenberry
Journal:  Clin Gastroenterol Hepatol       Date:  2012-09-14       Impact factor: 11.382

8.  Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer.

Authors:  R J C Steele; P L McClements; G Libby; R Black; C Morton; J Birrell; N A G Mowat; J A Wilson; M Kenicer; F A Carey; C G Fraser
Journal:  Gut       Date:  2008-11-26       Impact factor: 23.059

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force.

Authors:  Ann G Zauber; Iris Lansdorp-Vogelaar; Amy B Knudsen; Janneke Wilschut; Marjolein van Ballegooijen; Karen M Kuntz
Journal:  Ann Intern Med       Date:  2008-10-06       Impact factor: 25.391

View more
  88 in total

1.  Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue.

Authors:  Theodore R Levin; Douglas A Corley; Christopher D Jensen; Amy R Marks; Wei K Zhao; Alexis M Zebrowski; Virginia P Quinn; Lawrence W Browne; William R Taylor; David A Ahlquist; Graham P Lidgard; Barry M Berger
Journal:  Dig Dis Sci       Date:  2017-01-02       Impact factor: 3.199

2.  Inadequate Utilization of Diagnostic Colonoscopy Following Abnormal FIT Results in an Integrated Safety-Net System.

Authors:  Rachel B Issaka; Maneesh H Singh; Sachiko M Oshima; Victoria J Laleau; Carly D Rachocki; Ellen H Chen; Lukejohn W Day; Urmimala Sarkar; Ma Somsouk
Journal:  Am J Gastroenterol       Date:  2016-12-13       Impact factor: 10.864

3.  FITting ADR to colonoscopy indication.

Authors:  C Hassan; A Repici; D K Rex
Journal:  United European Gastroenterol J       Date:  2016-09-20       Impact factor: 4.623

4.  Optimizing the Quality of the Colorectal Cancer Screening Continuum: A Call to Action.

Authors:  Samir Gupta; Jesse Nodora
Journal:  J Natl Cancer Inst       Date:  2017-05-01       Impact factor: 13.506

5.  Beyond Colonoscopy: The Role of Alternative Screening Tests for Colorectal Cancer in Your Practice.

Authors:  Theodore R Levin
Journal:  Am J Gastroenterol       Date:  2016-11-01       Impact factor: 10.864

6.  Primary Care Provider Beliefs and Recommendations About Colorectal Cancer Screening in Four Healthcare Systems.

Authors:  Nirupa R Ghai; Christopher D Jensen; Sophie A Merchant; Joanne E Schottinger; Jeffrey K Lee; Jessica Chubak; Aruna Kamineni; Ethan A Halm; Celette Sugg Skinner; Jennifer S Haas; Beverly B Green; Nancy T Cannizzaro; Jennifer L Schneider; Douglas A Corley
Journal:  Cancer Prev Res (Phila)       Date:  2020-07-15

7.  A centralized mailed program with stepped increases of support increases time in compliance with colorectal cancer screening guidelines over 5 years: A randomized trial.

Authors:  Beverly B Green; Melissa L Anderson; Andrea J Cook; Jessica Chubak; Sharon Fuller; Richard T Meenan; Sally W Vernon
Journal:  Cancer       Date:  2017-07-28       Impact factor: 6.860

Review 8.  Multitarget stool DNA for colorectal cancer screening: A review and commentary on the United States Preventive Services Draft Guidelines.

Authors:  Barry M Berger; Bernard Levin; Robert J Hilsden
Journal:  World J Gastrointest Oncol       Date:  2016-05-15

Review 9.  Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

Authors:  Douglas J Robertson; Jeffrey K Lee; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas K Rex
Journal:  Am J Gastroenterol       Date:  2016-10-18       Impact factor: 10.864

10.  Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.

Authors:  Uri Ladabaum; Ajitha Mannalithara; Joel V Brill; Zachary Levin; Kate M Bundorf
Journal:  Am J Gastroenterol       Date:  2018-06-15       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.